Cellular Origins

On no! Our Easter eggs are missing, and we need your help to find them! 🐣 Check out our Easter short video 👉🎥 More than sharing chocolate eggs, we believe in working together to deliver our mission to enable scalable, efficient, and accessible life-saving treatments for patients worldwide.🌍 Happy Easter from all at Cellular Origins - and if you spot our eggs - Let us know!🥚 #HappyEaster #Easter2025 #CellTherapy

Stephen Ward has a great skill for ensuring that even though we have been talking about manufacturing in CGT for a long time, he keeps it relevant to the the current times. This is important given we have never had a bigger gap between demand for therapies and our ability to supply. Really interesting to hear Jason Treese and Jimmy V. insights, and reassuring that there are strong themes even across different parts of the industry.

We're off to Meeting on the Med... Will you be there? Our CEO, Edwin Stone and Global Business Development Lead, Jason Jones will be taking part on Day 1's agenda (details as below). We’d love to tell you more about Constellation, our mobile robotic ecosystem which is redefining what’s possible in cell therapy industrialisation. 📍 Hear us speak on Day 1 Edwin Stone, CEO – Panel discussion with Josh Ludwig, ScaleReady & Stephen Ward, Cell and Gene Therapy Catapult: 'Collaborative innovations in CGT manufacturing: Bridging reality and automation'. Jason Jones, Global BD Lead – Presentation: 'Why does CGT need to industrialise?'. 📆 If you'd like to connect with Edd or Jason while you’re there, send us a message to pre-book a 1:1. See you in Rome! #MeetingOnTheMed #CellTherapy #CGTManufacturing #Automation #ATMP #CGT #ModularAutomation

🔍 Automation in cell therapy: what does it actually mean? It's a term that's commonly used within cell therapy manufacturing, but what does it mean in practise, and does it refer to unit operation of process steps or a full end-to-end process? In our latest blog, we unpack the 3 types of automation you're likely to encounter: 1. End-to-End Automation – integrated, “box-like” systems. 2. Modular Automation – specialised instruments, manually connected. 3. Robotic Modular Ecosystems – like Cellular Origins’ Constellation – leveraging robotics to automate the connections and handling between modular instruments. 💡 Learn how each approach stacks up on sterility and risk, capital and space efficiency, as well as flexibility for process optimisation. Read the blog here: https://bit.ly/42qlz27

🎞️ What’s shaping the CGT industry? In a recent interview with PharmTech Group, our CEO Edwin Stone, highlighted two major industry shifts: the rise of GLP-1 drugs and the move of cell therapies into earlier lines of treatment. “The big question now is when cell therapies become first-line options, it all comes down to manufacturing and the cost of goods," states Edwin. He also points to solid tumours as an exciting frontier for cell therapies, following recent approvals from Iovance and Adaptimmune. “It shows the potential, but only if we can scale manufacturing effectively.” Looking ahead, he also flagged mRNA, diverse biologics, and new biological mechanisms as areas with huge potential to treat previously untreatable diseases. Watch the full interview here: https://bit.ly/4jwO6df

Full automation has the potential to transform CGT manufacturing but what does it actually involve, and when should you start thinking about it to scale effectively? Our CEO, Edwin Stone emphasises the importance of 'think early' but implement 'when the time is right for you'. This is a snippet from an AT-TV interview at #Advanced Therapies Week 2025 in Dallas earlier this year, with Benjamin McLeod. Catch the full video here: https://bit.ly/4l8VXPx

Unlock the roadmap to scalable cell and gene therapy manufacturing. As the CGT industry advances towards commercialisation, the pressure is on to deliver therapies at scale, without compromising on quality, cost-efficiency or regulatory confidence. Our recent eBook, Industrialising Cell and Gene Therapy Manufacturing, brings together expert perspectives from leaders across the industry, including Cellular Origins, Cell and Gene Therapy Catapult, Thermo Fisher, Cytiva, Fresenius Kabi, and ScaleReady, to address the key challenges facing therapy developers today. Discover how to: 🟨 Break through the barriers to scale-up 🟨 De-risk your path to industrialisation 🟨 Harness robotics, automation and digital tools to future-proof your manufacturing Whether you're navigating clinical to commercial transition or building the foundations for a robust, scalable manufacturing platform, this eBook is your essential guide. 📥 Download now and stay ahead of the curve: https://bit.ly/3ZQiecF #CellTherapy #GeneTherapy #CGTManufacturing #CellAndGeneTherapy #BiotechInnovation #Automation #Industrialisation #ATMP #AdvancedTherapies

🔬 Allogeneic, autologous, or in vivo? The cell therapy manufacturing landscape is rapidly evolving, and flexibility is more critical than ever. A recent article in Pharmaceutical-Technology highlights that autologous and allogeneic approaches continue to present unique challenges and opportunities. While scalability remains a key barrier for autologous therapies, innovation in decentralised, automated manufacturing is opening new doors. “Our modular robotics system enables small-scale, regional manufacturing; significantly reducing material transport times and allowing therapies to reach patients faster,” said Jason Jones, Global Business Development Lead at Cellular Origins, in a recent interview at Advanced Therapies 2025. "At Cellular Origins, we’re focused on industrialising cell therapy manufacturing. Our mobile robotic platform, Constellation, empowers therapy developers to scale with confidence - delivering flexibility, operational efficiency, and facility optimisation, without compromising process integrity. Whether you're navigating autologous or allogeneic pathways, a future-ready manufacturing solution is key to delivering therapies at scale". 📖 Read the full article here: https://bit.ly/43tUXiN #CellTherapy #ManufacturingInnovation #ConstellationPlatform #CellularOrigins #CGT #Autologous #Allogeneic #AdvancedTherapies #JasonJones #ModularManufacturing #DecentralisedProduction

Thanks for highlighting this Benjamin McLeod. What is industrialisation and what does it mean for cell therapy manufacturing? In the interview, our CEO, Edwin Stone references other industries that have used automation effectively to revolutionise throughput, and why industrialisation of cell therapy manufacturing is urgently needed to reach wider patient populations. Watch the full video here: https://bit.ly/4l8VXPx

We're Hiring! 🟨 Head of Systems Engineering 🟨 Senior Software Engineer 🟨 Senior Platform Engineer We currently have 3 great engineering roles at our premises in Cambridgeshire. Join us and play a pivotal role in shaping the future of our technology. Ready to make an impact? Find out more: https://bit.ly/4j0p9Xe #EngineeringLeadership #SystemsEngineering #softwareengineer #platformengineer #robotics #automation #vacancy